Month: June 2017
Population Pharmacokinetic of L-DOPA and Its Main Metabolites: Use of the Phoenix-based QRPEM Algorithm
Application of Global Sensitivity Analysis Methods to Determine the Most Influential Parameters of a Minimal PBPK Model of Quinidine
Certara Launches CODEx to Inform Comparative Effectiveness and Drug Development Decisions
PRINCETON, NJ – 2017 年 6 月 6 日 – Certara today launched its Clinical Outcomes Database Explorer (CODEx). An intuitive, web-based platform, CODEx enables drug development teams to easily visualize, explore, analyze and communicate content from Certara’s Clinical Trial Outcomes Databases and assess a given compound’s probability of success against competitor drugs.
Predicting Diclofenac Systemic and Synovial Fluid Concentrations After Dermal Application Using the Multi-phase Multi-layer MechDermA PBPK Model
Virtual Bioequivalence Assessment of Two Tramadol Formulations Using the Advanced Dissolution Absorption and Metabolism (ADAM) Model via Simcyp R Package
A Whole Body Physiologically-based Pharmacokinetic Model for Antibody Drug Conjugates—Model Development and Validation in Rat
Certara Pharmacometricians to Highlight Modeling and Simulation Advances at PAGE 2017
PRINCETON, NJ – 2017 年 6 月 5 日 – Certara today announced that its scientists are playing leading roles in more than 30 sessions at the Population Approach Group in Europe (PAGE) 2017 Annual Meeting. PAGE is a UK-based, nonprofit organization, which is committed to taking a population approach to data analysis. This year’s meeting is being held in Budapest, Hungary from June 6-9.
Time Dependent Pharmacokinetics of Pembrolizumab in Patients with Solid Tumor and Its Correlation with Best Overall Response
Obeticholic Acid—From PK Model to Drug Label
Watch this webinar with Jeffrey Edwards to learn how he used physiologic pharmacokinetic modeling to understand the relationship between systemic and hepatic exposure of OCA in patients with and without hepatic impairment. By watching this webinar, you will learn how pharmacokinetic modeling can support optimal dosing for patients with organ impairment and facilitate regulatory approval.
